Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Idera Pharmaceuticals has stopped patient enrollment early for its Phase II trial on a candidate melanoma drug after interim data delivered impressive results.
As Scholar Rock prepares to move forward with its experimental assets for spinal muscular atrophy, it has terminated 25% of its staff and also announced the loss of its chief medical officer.
Dark Horse Consulting Group (DHC), based in Walnut Creek, Calif., submitted proposed draft guidance to the FDA for gene therapy safety.
CRISPR Therapeutics tapped Amgen veteran Phuong Khanh (P.K.) Morrow, M.D., FACP, as its new chief medical officer.
COVID-19 would have claimed over 110,000 more lives in 2021 if vaccines weren’t available, according to a Pfizer-sponsored report on the first year of the U.S. vaccination program.
The ASGCT’s 25th Annual Meeting features the latest scientific research in genetics and cellular therapies. Read on for highlights from the meeting.
Evotec and Sernova partnered to develop an implantable induced pluripotent stem cell (iPSC)-based beta cell replacement therapy that can be used to treat both type 1 and 2 diabetes patients.
Researchers continue to explore how to turn deadly venom into life-saving drugs. Several papers on the subject have recently been published and BioSpace is taking a look at them.
During the past several years, data generation, data mining and analytics have progressed to the point that it is now possible to bring precision medicine to psychiatry.
Agios Pharmaceuticals is cutting its staff numbers by 50 as part of plans to lay low on exploratory research efforts to focus on the success of late-stage initiatives.
Cugene and AbbVie came together on autoimmune diseases and cancer, while Proteros and AstraZeneca expanded their collaboration on epigenetic cancer drugs.
In honor of ALS Awareness Month, BioSpace spoke with leading researchers like Dr. Matthew Harms of Columbia University and Drs. Howard Berman and Stanley Appel at Coya Therapeutics.
